European Hematology Association - Clinical Trial Efficacy of CAR-T Therapy in Patients with Diffuse Large B-cell Lymphoma Is Mirrored in the Real World - il Centro Tirreno - Quotidiano online
Il sito "il Centro Tirreno.it" utilizza cookie tecnici o assimiliati e cookie di profilazione di terze parti in forma aggregata a scopi pubblicitari e per rendere più agevole la navigazione, garantire la fruizione dei servizi, se vuoi saperne di più leggi l'informativa estesa, se decidi di continuare la navigazione consideriamo che accetti il loro uso.
13
Dom, Giu

European Hematology Association - Clinical Trial Efficacy of CAR-T Therapy in Patients with Diffuse Large B-cell Lymphoma Is Mirrored in the Real World

Immediapress
Typography
  • Smaller Small Medium Big Bigger
  • Default Helvetica Segoe Georgia Times

THE HAGUE, Netherlands, June 11, 2021 /PRNewswire/ -- DESCAR-T is the French national registry for patients treated with commercial chimeric antigen receptor (CAR)-T cells across all hematological malignancies aimed to collect real-world data including safety and effectiveness up to 15 years after CAR-T cell infusion. Several complementary

registries are also linked to the DESCAR-T database such as an immune-monitoring database, a blood and tumor biobank, and an imagery platform. In this study, we aimed to analyze patient characteristics and clinical outcome of 537 patients with diffuse large B-cell lymphoma who were registered in the DESCAR-T database. 

Approximately 50 new patients were registered each month, demonstrating the success of CAR-T therapy. Of the registered patients, CAR-T cells were ordered for 607 patients and 550 had been infused. The median time from CAR-T order to infusion was 50 days. Of the patients who completed CAR-T therapy, 350 pts were infused with Axi-cel and 200 received Tisa-acel. Analyzing the response data from 460 infused patients, we found that 40 % achieved complete remission and 30% achieved partial remission by Day 30. The progression-free survival at 6 months calculated from the time of CAR-T infusion was 44.5% [39.6-49.2] months. In conclusion, our analysis of the DESCAR-T registry confirmed the clinical trial efficacy of CAR-T therapy in the real world. 

The results of this study will be presented by Professor Steven Le Gouill in an oral session. 

Presenter:  Professor Steven Le Gouill 

Affiliation:  CHU de Nantes,  Nantes, France 

Abstract:  #S216  FIRST RESULTS OF DLBCL PATIENTS TREATED WITH CAR-T CELLS AND ENROLLED IN DESCAR-T REGISTRY, A FRENCH REAL-LIFE DATABASE FOR CAR-T CELLS IN HEMATOLOGIC MALIGNANCIES. 

About the EHA Annual Congress: Every June, EHA organizes its Annual Congress in a major European city. This year, due to the persisting COVID19 pandemic, EHA organizes a virtual Congress for the second time. The Congress is aimed at health professionals working in or interested in the field of hematology.  

Website: www.ehaweb.org  

Logo - http://mma.prnewswire.com/media/622259/EHA_Logo.jpg